» Articles » PMID: 36672151

Pathogenic Th2 Cytokine Profile Skewing by IFN-γ-Responding Vitiligo Fibroblasts Via CCL2/CCL8

Overview
Journal Cells
Publisher MDPI
Date 2023 Jan 21
PMID 36672151
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Vitiligo is a T cell-mediated skin depigmentation disease. Though treatments arresting disease progression and inducing repigmentation are available, the efficacy of these options is often limited and poorly sustained. How stromal signals contribute to the interferon-γ-dominant skin niches is unclear. This study aims to determine how fibroblasts participate in the IFN-γ-dominant vitiligo niche.

Patients And Methods: Mouse vitiligo models were established. Fibroblasts from control and vitiligo mice were extracted for RNA sequencing. In vitro IFN-γ stimulation was performed to verify the JAK-STAT pathway by qPCR and Western blot. T cell polarization with chemokines was measured by flow cytometry. Protein levels in tissues were also examined by IHC.

Results: The vitiligo mouse model recapitulates the human CD8-IFN-γ pathway. RNA sequencing revealed elevated chemokine CCL2 and CCL8 in vitiligo fibroblast, which may be regulated by the JAK-STAT signaling. Such phenomenon is verified by JAK inhibitor peficitinib in vitro. Moreover, CCL2 addition into the naïve T polarization system promoted type 2 cytokines secretion, which represents a hallmark of vitiligo lesions.

Conclusion: Dermal fibroblasts, a principal constituent of skin structure, respond to IFN-γ by skewing T cells towards a type 2 cytokine profile via CCL2 and CCL8, which can be abrogated by JAK inhibitor peficitinib.

Citing Articles

Biologic drugs induced vitiligo: case reports and review of literature.

Shao X, Chen T, Pan X, Chen S, Chen Y, Chen J Front Immunol. 2025; 15:1455050.

PMID: 39742272 PMC: 11685107. DOI: 10.3389/fimmu.2024.1455050.


Exploring mechanisms of skin aging: insights for clinical treatment.

Zhang M, Lin Y, Han Z, Huang X, Zhou S, Wang S Front Immunol. 2024; 15:1421858.

PMID: 39582871 PMC: 11581952. DOI: 10.3389/fimmu.2024.1421858.


Role of fibroblasts in nonfibrotic autoimmune skin diseases.

He Y, Han Z, Zhang Q, Liu L, Chang J Mol Med. 2024; 30(1):178.

PMID: 39420283 PMC: 11488258. DOI: 10.1186/s10020-024-00949-x.


Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics.

Chen X, Wu Y, Jia S, Zhao M Clin Rev Allergy Immunol. 2024; 66(3):274-293.

PMID: 38940997 DOI: 10.1007/s12016-024-08997-1.


Early short-term hypoxia promotes epidermal cell migration by activating the CCL2-ERK1/2 pathway and epithelial-mesenchymal transition during wound healing.

Jin L, Zhou S, Zhao S, Long J, Huang Z, Zhou J Burns Trauma. 2024; 12:tkae017.

PMID: 38887221 PMC: 11182653. DOI: 10.1093/burnst/tkae017.


References
1.
Relke N, Gooderham M . The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. J Cutan Med Surg. 2019; 23(3):298-306. DOI: 10.1177/1203475419833609. View

2.
Chen D, Xu Z, Cui J, Chen T . A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte. Cell Regen. 2022; 11(1):31. PMC: 9526765. DOI: 10.1186/s13619-022-00132-9. View

3.
Antonelli A, Ferrari S, Fallahi P . The role of the Th1 chemokine CXCL10 in vitiligo. Ann Transl Med. 2015; 3(Suppl 1):S16. PMC: 4437934. DOI: 10.3978/j.issn.2305-5839.2015.03.02. View

4.
Riding R, Richmond J, Harris J . Mouse Model for Human Vitiligo. Curr Protoc Immunol. 2018; 124(1):e63. PMC: 6340773. DOI: 10.1002/cpim.63. View

5.
Frisoli M, Essien K, Harris J . Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020; 38:621-648. DOI: 10.1146/annurev-immunol-100919-023531. View